Oncology Research Award – Swiss Cancer Institute, Atellas Pharma & Astra Zeneca
Share this opportunity
Apply before 27 April 2026 for the Swiss Cancer Institute / Astellas Pharma & AstraZeneca Translational GU‑Oncology Research Award 2026
Are you conducting translational research in genitourinary (GU) oncology? This is your opportunity to propel your work forward!
The Swiss Cancer Institute, together with Astellas and AstraZeneca, is awarding CHF 10,000 to support an outstanding translational GU oncology project aimed at bringing scientific discoveries closer to clinical practice.
Eligible projects include, but are not limited to:
• Development of novel treatments for GU cancers (small molecules, biologics, radioligand therapies)
• Innovations in diagnostic modalities
• Novel prevention strategies
• Preclinical, animal, human tissue, or human studies
⚠️ Projects must be translational and conducted in Switzerland
Who can apply?
Researchers with their primary workplace in Switzerland—graduate students, postdocs, or physician‑scientists who are involved in translational or clinical research.